u/tomas_lokken

Agreed. The dry powder is the robust state; it is the solution that needs the care.

I would not generalise from one bad month to a rule. The rest of your process sounds fine.

Not convinced that was avoidable. Some of this is genuinely bad luck and treating everything as a lesson is its own trap.

Most of what gets posted here is procedural rather than dramatic: a step skipped, a document not requested, a temperature not considered, a pace chosen out of impatience.

Kept fingersticks alongside the sensor for two weeks to sanity-check it. Worth doing once.

keep the script and the receipt for private health claims

Correction: that trial is the diabetes programme and the figure you quoted is its glycaemic endpoint, not a weight result.

I would not freeze it in solution. That is a different failure mode and a worse one.

the goal weight you picked at week 1 was a guess

This reframing is the most useful thing on the board for anyone approaching this phase.

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth less than usual.

What was the packaging — rigid outer, gel packs, anything insulating?

a summer lane and a winter lane are different lanes

That figure is from the obesity programme, and this thread is about the hepatic one.

What does your weigh-in frequency look like at this point?

The habits from the losing phase are what carry it now. That is not inspirational, it is just what happened.

This. The withdrawal data is not ambiguous and framing regain as a personal failure is both wrong and cruel.

this board exists so the failures are on the record too

going up too fast is the most repeated regret on this board

this board is small because the compound is early

Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.

Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.

Registration by the therapeutic goods regulator establishes that a product may be supplied. Subsidy listing is a separate decision about public funding, with its own criteria and its own timetable.

Not convinced that was avoidable. Some of this is genuinely bad luck and treating everything as a lesson is its own trap.

A transit temperature logger records a distribution, and time above a threshold matters as much as peak temperature. That is the argument for logging rather than guessing.

Kept fingersticks alongside the sensor for two weeks to sanity-check it. Worth doing once.

the habits are the part that has to outlive the dose

Asked the pharmacist to check the wholesaler and had a definite answer in about four minutes.

What does your weigh-in frequency look like at this point?

regain after stopping is the expected outcome, not a personal failure

Same. Private pricing varies here as much as anywhere and people assume it is fixed.

Correction: that is the registration decision, not the subsidy listing. They are made by different bodies.

What does your weigh-in frequency look like at this point?

That is a lane problem rather than a packaging problem, and the fixes are different.

maintenance is where the logistics finally get boring, which is the point

regional stock removes most of this problem entirely

Yes — histological endpoints are a far harder bar than the surrogate measures people are used to quoting.

Pharmacy-level availability and national supply are different questions: a pharmacy can be out while the wholesaler is not, and the pharmacist can check in minutes.

independent testing on this compound is very thin

I would not compare your numbers to that population. Different baseline, different regimen, different trial.

not approved anywhere, and the boards forget that constantly